Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer

Breast Care

Volumn 9, Issue 4, 2014, Pages 283-286

  Bauerschlag, Dirk O ^a   Maass, Nicolai ^a   Schem, Christian ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Aromatase inhibitor; CYP2D6; Endocrine resistance; Endocrine treatment; Postmenopausal status; Premenopausal status; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CLODRONIC ACID; CYTOCHROME P450 2D6; ESTRADIOL; EXEMESTANE; FOLLITROPIN; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; ZOLEDRONIC ACID;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; EARLY BREAST CANCER; GENOTYPE; HEALTH CARE QUALITY; HORMONE BLOOD LEVEL; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW;

EID: 84929469596     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000365561     Document Type: Review

References (15)

1. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopp ing at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-816.
2. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-1467.
3. Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R: Use of luteinising-hormone-re leasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A metaanalysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711-1723.
4. Thurlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A: Is chemotherapy necessary for premenopausal women with lower-risk n ode-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 2009;113:137-144.
5. Regan MM, Pagani O, Fleming GF, Wal ley BA, Price KN, Rabaglio M, Maibach R, Ruepp B, Coates AS, Goldhirsch A, Colleoni M, Gelber RD, Francis PA: Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the T EXT and SOFT trials. Breast 2013;22:1094-1100.
6. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Lang I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thurlimann B: Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 2011;12:1101-1108.
7. Dubsky PC, Jakesz R, Mlineritsch B, Postlberger S, Samonigg H, Kwasny W, Tausch C, Stoger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M: Tamoxifen and anastrozole as a sequencing strategy: A randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Aust rian Breast and Colorectal Cancer Study Group. J Clin Oncol 2012;30:722-728.
8. Boccardo F, Guglielmini P, Bordonaro R, Fini A, Massidda B, Porpiglia M, Roagna R, Serra P, Orzalesi L, Ucci G, Rubagotti A: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial. Eur J Cancer 2013;49: 1546-1554.
9. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Pal mer MJ, Tu D: Late extended adjuvant treatment with letrozole improves outcome in women with earlystage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:1948-1955.
10. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Livingston RB, Davidson NE, Perez EA, Chavarri-Guerra Y, Cameron DA, Pritchard KI, Whelan T, Shepherd LE, Tu D: Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol 2013;24:355-361.
11. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbe s JF: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11:1135-1141.
12. Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R: Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: A metaanalysis. Lancet Oncol 2006;7:991-996.
13. Hadji P Body JJ Aapro MS Brufsky A Coleman RE Guise T Lipton A Tubiana-Hulin M. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008 19 1407-1416.
14. Dezentje VO, Van Schaik RH, Vletter-Bogaartz JM, Van Der Straaten T, Wessels JA, Kranenbarg EM, Berns EM, Seynaeve C, Putter H, Van de Velde CJ, Nortier JW, Gelderblom H, Guchelaar HJ: CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Res Treat 2013;140:363-37 3.
15. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012;104:452-460.